Living with diffuse large B-cell lymphoma, the decisions and the people who make them: This is orientation from public patient pages, guidelines and the trials themselves, not advice for your case: your own team's instructions and the 24-hour number they gave you come first, and no figure here is a prediction about you. The decision records, the question sets, the first 60 days checklist and the red cards on this page were written from the NHS, Lymphoma Action, Macmillan and Cancer Research UK patient pages, from NICE NG52, NG47, CG151 and NG234, from the NHS Breast Screening Programme protocols and the Green Book, and from the trial reports named beside each figure, all read on 1 October 2026.
On the second-linedecision. The figures in the decision record come from the trials' own publications: ZUMA-7randomised 359 people and reported 24-month event-free survival of 41 per cent against 16 per cent, and four-year overall survival of 54.6 against 46.0 per cent at a median follow-up of 47.2 months; BELINDA randomised 322 people to a different cell product and found median event-free survival of 3.0 months in both arms. They describe those trial populations, not any one person, and the people in them were selected for early relapse.
Machine-readable versions
The same record for scripts and assistants; checked 2026-09-07. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.